Strong Q1 Sets High Bar—Can Margins Hold?
After a stellar Q1 FY27 with 35% YoY revenue growth and an 80% profit surge, Elantas Beck faces the test of consistency. The real watch: whether the sharp 28.8% EBITDA margin can sustain amid a CFO transition.
The Setup: Q1 Momentum—Now Hold It
Elantas Beck opened FY27 with a bang: Q1 revenue reached ₹283.39 Cr (up 35% YoY from ₹209.93 Cr), and standalone net profit surged 80.4% to ₹70.86 Cr. EBITDA margins expanded smartly to 28.83% from 18.88% a year prior—a 195-basis-point jump that signals either operational leverage, favorable product mix, or pricing power kicking in. The bar for Q2 is now very high. Street expectations point to continued 30–35% YoY revenue growth on-plan, with margin sustainability testing the thesis.
~₹280–300 Cr
35% YoY growth on-plan based on Q1 trajectory
~27–29%
sustain Q1 gains; watch for cost inflation or mix shifts
~₹70–80 Cr
20–30% YoY growth if margins hold
~₹5.50–6.30
FY27 consensus avg ₹0.66 (~₹52 annual equivalent)
What Good vs Weak Looks Like
A strong Q2 print: Revenue lands at the ₹280+ Cr mark with YoY growth holding 30%+. EBITDA margin stays above 27%, signaling that Q1's operational wins (cost control, mix improvement, or pricing) are repeatable. Management reiterates FY27 guidance confidently, and the CFO transition appears orderly with no red flags. A weak print: Revenue softens to sub-₹260 Cr or YoY growth falls below 25%, suggesting demand headwinds or market share loss. EBITDA margin contracts to below 26%, pointing to unplanned cost inflation or adverse mix. Any cautious commentary on guidance or uncertainty around the CFO transition could trigger a sell-off, especially given the stock's premium valuation (trading near ATH after a 74% run from the 52-week low).
On Track for Full-Year Guidance?
Elantas Beck is a specialty chemicals leader in electrical insulation (>80% of revenue) with 35%+ market share. Q1 FY27 already printed 35% YoY growth and 28.8% EBITDA margins—well ahead of the long-term earnings growth rate of 17% baked into historical guidance. Unless the company surprises with an upgrade on Oct 28, the consensus seems to be riding Q1's momentum into a strong FY27 full year. However, the CFO resignation (Oct 21, effective immediately) injects uncertainty—management will need to reassure investors that this is a planned succession, not a knee-jerk exit.
Since Last Quarter: Events & Risks
Oct 22, 2026
Risk / WatchCFO Resignation: Sanjay Kulkarni resigns effective Oct 21
Oct 14, 2026
RoutineBoard Meeting scheduled for Oct 28 to approve Q2 FY27 results
Oct 1–Oct 27, 2026
RoutineTrading window closure for Q2 FY27 results
The CFO transition is the key wildcard. Sanjay Kulkarni's Oct 21 departure (cited as 'personal reasons') comes just one week before the Q2 results announcement. While board meetings and trading window closures are routine, a CFO exit mid-quarter—especially at a premium-valued specialty chemicals company riding high on 35% growth—raises questions about knowledge transfer and internal confidence. Management will need to confirm a successor and rule out any underlying operational concerns. Ownership remains stable: promoter 75%, DII 12.28%, FII 0.05% (no material changes recent quarters). No insider pledges or block deals flagged.
1 · Revenue Growth Sustainability
Q1's 35% YoY growth was exceptional. Watch whether Q2 maintains 30%+ YoY growth or softens. Any deceleration below 25% would signal demand headwinds or market share loss and could trigger a sell-off given the premium valuation.
2 · EBITDA Margin Hold
The 28.8% EBITDA margin in Q1 was a 195-bp jump YoY. Confirm whether this reflects durable operational leverage or one-time mix benefits. A margin sustained above 27% is a 'good' print; anything below 26% is a warning flag.
3 · CFO Succession & Guidance
Expect management to name a new CFO or interim replacement on the call. Any hint of execution risk, delayed hiring, or cautious commentary will be scrutinized. Reaffirm or raise FY27 guidance; silence or a guidance cut would compound the Oct 21 resignation signal.
Elantas Beck has set itself up as a FY27 earnings growth story, with Q1 delivering 35% revenue and 80% profit growth. The Oct 28 print is a test of consistency: can margins hold, is demand durable, and will the CFO transition be seamlessly managed? A strong Q2 (₹280+ Cr revenue, 27%+ EBITDA margin, upbeat guidance, orderly succession) reinforces the bull case; any stumble risks a sharp pullback given the stock's premium valuation and thin analyst coverage. The next 72 hours will be defining.
Elantas Beck Q2FY27: Standalone PAT +26% YoY, but margin cools to 22.9% from Q1's 28.8% high
PAT +25.62% YoY · revenue +22.52% · margins compressing · miss vs street
₹265.31 Cr
+22.52% YoY
₹45.55 Cr
+25.62% YoY
16.76%
+0.6pp YoY
₹57.45
Elantas Beck India's standalone revenue for the September quarter came in at ₹265.31 Cr, up 22.5% YoY from ₹216.55 Cr, while PAT rose 25.6% YoY to ₹45.55 Cr from ₹36.26 Cr — solid double-digit growth on both lines, with EPS at ₹57.45 versus ₹45.74 a year ago. Margins were also marginally better YoY: OPM (EBITDA-equivalent) expanded 1.2 points to 22.95% from 21.79%, and NPM edged up 0.6 points to 16.76% from 16.20%. On a year-on-year basis this is a continuation of growth, not a reversal.
Q2 FY-2027 vs prior quarters
But the quarter is a clear sequential slowdown and a miss against the bar we set pre-result. Revenue fell 6.4% QoQ and PAT fell 35.7% QoQ from Q1 FY27's ₹70.86 Cr, as OPM compressed sharply — down 5.9 points from Q1's 28.83% to 22.95%, and NPM down 6.6 points from 23.41% to 16.76%. Our pre-result preview flagged exactly this risk ("can margins hold?") and set an expected band of revenue ₹280–300 Cr, EBITDA margin 27–29% and PAT ₹70–80 Cr; the actual print undershot all three, confirming the margin-sustainability watch item rather than resolving it favourably. Street coverage on this name is thin (per the preview, no published consensus target), so there is no independent numeric consensus to benchmark against beyond our own pre-result range — against that range, this quarter is a miss. Management gives no formal guidance on record (none in our database, none found via web search), so there is no company outlook to grade this against either.
The stock went into the print at ₹12,800, down 8.3% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Segment-wise, Electrical Insulations (about 75% of revenue) grew 15.9% YoY to ₹199.96 Cr but fell 11.0% QoQ, while Engineering & Electronic Resins and Materials grew faster at 49.1% YoY to ₹65.40 Cr and was up 11.2% QoQ — the smaller resins segment partly cushioned the larger insulation segment's sequential dip. Two of the three pre-result watch items moved this quarter: the CFO transition flagged in the preview is now resolved, with Ms. Supriya Bansal appointed CFO effective October 28, 2026 following Sanjay Kulkarni's October 22 resignation; separately, the GPCB granted a permanent revocation of the long-standing Ankleshwar closure order on October 27, 2026, clearing a legacy regulatory overhang referenced in the filing's notes (no direct P&L impact this quarter).
W1
Whether OPM recovers toward the 27-29% range seen pre-result or 22-23% becomes the normalized run-rate
W2
Electrical Insulations segment's sequential trajectory (-11.0% QoQ this quarter) given it is ~75% of revenue
W3
New CFO Supriya Bansal's first full quarter at the helm, following the Oct 28, 2026 appointment
Only a single (standalone) statement exists — company has no consolidated section. Figures are unaudited, limited-review only. No exceptional items in current or year-ago quarter; GPCB granted permanent revocation of the 2019 Ankleshwar closure order on Oct 27, 2026 (regulatory note, not a P&L item).